Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology.
Paterson RW, Heywood WE, Heslegrave AJ, Magdalinou NK, Andreasson U, Sirka E, Bliss E, Slattery CF, Toombs J, Svensson J, Johansson P, Fox NC, Zetterberg H, Mills K, Schott JM. Paterson RW, et al. Among authors: zetterberg h. Transl Psychiatry. 2016 Nov 15;6(11):e952. doi: 10.1038/tp.2016.194. Transl Psychiatry. 2016. PMID: 27845782 Free PMC article.
Cystatin C in cerebrospinal fluid and multiple sclerosis.
Hansson SF, Simonsen AH, Zetterberg H, Andersen O, Haghighi S, Fagerberg I, Andréasson U, Westman-Brinkmalm A, Wallin A, Rüetschi U, Blennow K. Hansson SF, et al. Among authors: zetterberg h. Ann Neurol. 2007 Aug;62(2):193-6; discussion 205. doi: 10.1002/ana.20945. Ann Neurol. 2007. PMID: 16900522
Longitudinal stability of CSF biomarkers in Alzheimer's disease.
Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P, Basun H, Andreasen N. Blennow K, et al. Among authors: zetterberg h. Neurosci Lett. 2007 May 23;419(1):18-22. doi: 10.1016/j.neulet.2007.03.064. Epub 2007 Apr 6. Neurosci Lett. 2007. PMID: 17482358
Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years.
Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerström C, Syversen S, Mattsson UB, Ysander C, Mattsson N, Nordlund A, Vanderstichele H, Vanmechelen E, Jonsson M, Edman A, Blennow K, Wallin A. Zetterberg H, et al. J Alzheimers Dis. 2007 Nov;12(3):255-60. doi: 10.3233/jad-2007-12307. J Alzheimers Dis. 2007. PMID: 18057559
Clinical proteomics in neurodegenerative disorders.
Zetterberg H, Rüetschi U, Portelius E, Brinkmalm G, Andreasson U, Blennow K, Brinkmalm A. Zetterberg H, et al. Acta Neurol Scand. 2008 Jul;118(1):1-11. doi: 10.1111/j.1600-0404.2007.00985.x. Epub 2008 Feb 13. Acta Neurol Scand. 2008. PMID: 18279484 Review.
Targeted proteomics in Alzheimer's disease: focus on amyloid-beta.
Portelius E, Zetterberg H, Gobom J, Andreasson U, Blennow K. Portelius E, et al. Among authors: zetterberg h. Expert Rev Proteomics. 2008 Apr;5(2):225-37. doi: 10.1586/14789450.5.2.225. Expert Rev Proteomics. 2008. PMID: 18466053 Review.
2,237 results